United Therapeutics (UTHR) announced full enrollment of the TETON 1 study evaluating the use of Tyvaso or treprostinil, inhalation solution or nebulized Tyvaso, for the treatment of idiopathic ...

In a worst-case scenario, Liquidia should be able to have a full commercial launch after May 23rd of next year, when the three-year exclusivity granted to TYVASO DPI® by the FDA expires.

Dosage for transition from Tyvaso Inhalation Solution: see full labeling. Risk of symptomatic hypotension in those with low systemic arterial pressure. Hepatic insufficiency; titrate slowly.

TYVASO (treprostinil ... by the inhalation route are altered by inhibitors or inducers of CYP2C8. Limited case reports of treprostinil use in pregnant women are insufficient to inform a drug ...